ObjectiveTo summarize research progress on programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors and their combination therapies in colorectal cancer and to provide a new treatment direction for colorectal cancer.MethodThe relevant literatures on the application of the PD-1/PD-L1 inhibitors in the colorectal cancer in recent years were collected and reviewed.ResultsThe clinical trials of anti-PD-1/PD-L1 signaling pathway antibodies had made some achievements in the colorectal cancer, especially in the patients with high frequency microsatellite instability. And the combination therapy of multiple antibodies and the combination with chemotherapy and targeted therapies were more effective.ConclusionPD-1/PD-L1 inhibitors have some certain curative effects on survival of colorectal cancer with high frequency microsatellite instability, especially combination shows a better effect.
In recent years, atezolizumab, a programmed death-ligand 1 (PD-L1) has shown clinical efficacies against many different solid malignancies. In late October 2016, the Food and Drug Administration (FDA) granted approval to atezolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. With the development of clinical trials, the applications of atezolizumab in lung cancer treatment have gradually expanded. In this review, we summarized the current clinical status of atezolizumab in the treatment of lung cancer.
Lung cancer is the leading cause of cancer-related deaths worldwide. Although improvement has been achieved in platinum-based chemotherapy and tyrosine kinase inhibitors-based molecular targeted therapy, they still have limitations. Immunotherapy has recently emerged as a very effective new treatment, and there is now growing enthusiasm in cancer immunotherapy worldwide. We summarized the effects of immune checkpoint inhibitors in clinical trials, and the current status and progress of anti programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) agents in lung cancer treatment. Attention has been paid to finding out the factors which influence the therapeutic effect of anti-PD-1/PD-L1 therapy and reducing the occurrence of adverse events.
ObjectiveTo analyze the status of applying programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors combined with vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors in advanced refractory colorectal cancer. MethodThe relevant literature on domestic and foreign research in recent years was summarize. ResultsThe discovery of immune checkpoint PD-1/PD-L1 and the clinical application of related drugs have changed the treatment pattern of advanced solid tumors, but PD-1/PD-L1 inhibitors have poor efficacy in mismatch repair prodicient tumors, and most advanced colorectal cancer belongs to this type. The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors can enhance the therapeutic effect in advanced refractory colorectal cancer, and their interaction mechanisms and clinical efficacy are continuously being proven. ConclusionsThe combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors is a promising treatment strategy for advanced refractory colorectal cancer. More studies are needed to further clarify its efficacy.